Verastem, Inc. (NASDAQ: VSTM) is a Healthcare company (Biotechnology) with a market capitalization of $934M. The Maz Rating grades it against the other companies in its sector.
Verastem, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.41, Verastem, Inc. trades at 9.3x sales and 74.4x book value. Over the last twelve months it generated about $100M of revenue and a net loss of $233M. It runs a gross margin of 86.1%, an operating margin of -193.7% and a net margin of -178.4%. It shows return on equity of -359.5%, return on invested capital of -145.6% and a free cash flow yield of -17.2%. On the balance sheet: a debt-to-equity ratio of 12.09 and a current ratio of 1.93. Over the past 52 weeks the share price ranged from $3.43 to $10.82, with a beta of 0.32.
Verastem, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 15 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Verastem, Inc. (VSTM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 14.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 21.0% / 30% · Interest income / Revenue 3.19% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 14.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 21.0% / 33% · Receivables / Mkt Cap (36m) 1.22% / 49% · Interest income / Revenue 3.19% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 14.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 21.0% / 33.33% · Receivables / Mkt Cap (24m) 1.22% / 33.33% · Interest income / Revenue 3.19% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 40.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 77.4% / 33.33% · Receivables / Avg Assets (4Q) 5.46% / 33.33% · Interest income / Revenue 3.19% / 5% | Fail |
| FTSE | Debt / Total Assets 52.0% / 33.33% · (Cash+ST Inv) / Total Assets 75.2% / 33.33% · (Cash+Recv) / Total Assets 79.6% / 33.33% · Interest income / Revenue 3.19% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Verastem, Inc. (VSTM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Verastem, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.19% of each dividend: Verastem, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.